The Ademi Firm is investigating Cidara (Nasdaq: CDTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.

https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.jpg

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the tender offer transaction, Cidara shareholders will receive $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. Cidara insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Cidara by imposing a significant penalty if Cidara accepts a competing bid. We are investigating the conduct of the Cidara board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP Guri AdemiToll Free: (866) 264-3995Fax: (414) 482-8001

https://edge.prnewswire.com/c/img/favicon.png?sn=CG24862&sd=2025-11-14

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-cidara-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302615652.html

SOURCE Ademi LLP

https://rt.newswire.ca/rt.gif?NewsItemId=CG24862&Transmission_Id=202511141008PR_NEWS_USPR_____CG24862&DateId=20251114

COMTEX_470251915/1005/2025-11-14T10:08:34